Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Clinical trial NCT04478266 · TERMINATED
Trial details
- NCT number
- NCT04478266
- Sponsor
- Sanofi
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-14
- Primary completion
- 2022-06-28
- Enrollment
- 1068
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.